Before the Bell Scans of PDLI, BCRX, ARRY, and RPRX Provides Stock Research on PDL BioPharma Inc., BioCryst Pharmaceuticals Inc., Array BioPharma Inc., and Repros Therapeutics Inc.

New York City, New York -- (May 02, 2013)

The “patent cliff”, which refers to the expiration of patent on several blockbuster drugs over the next few years, is having a significant impact on major drug companies’ top-lines. According to estimates from EvaluatePharma, in 2013 alone, patents on drugs with annual sales of nearly $29 billion will expire. In order to minimize the impact of the patent cliff, major drug manufacturers have been looking to boost their product pipelines by increasing research & development activities. Major drug manufacturers are also looking collaborate to with innovative biotechnology companies. The development has also made several biotechnology companies as potential takeover targets. Biotechnology stocks ended mostly lower on Wednesday, tracking losses in the broad market. Among the major movers were PDL BioPharma Inc. (NASDAQ: PDLI), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Array Biopharma Inc. (NASDAQ: ARRY), and Repros Therapeutics Inc. (NASDAQ: RPRX). StockCall has taken an interest in these companies and you can now sign up to download the free technical research on PDLI, BCRX, ARRY, and RPRX at

PDL BioPharma Inc.’s shares fell sharply in Wednesday’s trading session. The stock traded between $7.59 and $7.78 before finishing the day 1.94% lower at $7.59 on above average volume of 1.76 million. PDL BioPharma’s shares have seen a pullback after having enjoyed an excellent run since February. The stock saw a series of highs since February. However, the stock’s MACD has just crossed below the signal line which suggests that the bullish trend has come to an end. The company’s shares currently have support at around $7.50. Sign up today to read the free research report on PDLI at

Another major loser in the biotechnology sector yesterday was BioCryst Pharmaceuticals Inc. Shares of the Durham, North Carolina-based biotechnology company ended 4.98% lower at $1.91 on above average volume of 2.60 million. Despite the sharp decline on Wednesday, BioCryst’s shares have gained more than 34.50% thus far in 2013 as compared to a gain of nearly 11% for the S&P 500. The stock, however, has been facing stiff resistance at around $2. Register to download the free technical analysis on BCRX at

Shares of Array Biopharma Inc. also fell sharply in yesterday’s trading session. The stock fell to an intra-day low of $5.65 before finishing the day 4.54% lower at $5.68 on above average volume of 1.42 million. Array’s shares have had an excellent run so far this year, gaining nearly 52.70%. However, the stock has seen a series of lows over the last few sessions which suggests that market sentiment has turned bearish. The stock’s MACD has also crossed below the signal line which further confirms the bearish trend. Free report on ARRY can be accessed by registering at

Repros Therapeutics Inc.’s shares tumbled in trading on Wednesday. The stock traded between $18.68 and $20.48 before finishing the day 6.59% lower at $19 on volume of 472,045. Despite the sharp decline yesterday, the company’s shares are currently trading close to their 52-week high of $20.78. The stock’s MACD has just crossed below the signal line which is a bearish signal. Year-to-date, however, shares of RPRX are still up more than 20.60%, outperforming the S&P 500. Register withStockCall and download the research on RPRX for free at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

Contact Person:

William T. Knight


Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here